1cBio, Inc. Company Profile
Background
1cBio, Inc. is an emerging biotechnology company headquartered in the San Francisco Bay Area, dedicated to developing precision medicines for significant unmet medical needs. Established in 2022, the company focuses on mechanisms of action validated through clinical practice, trials, or preclinical models. Their mission is to identify gaps in disease treatments and develop highly differentiated molecules for precision medicine.
Key Strategic Focus
1cBio specializes in oncology and rare diseases, aiming to treat conditions and preemptively counter mechanisms for acquired or intrinsic resistance. Their core expertise lies in medicinal chemistry and translational sciences, guided by collaborations with clinical and basic science experts.
Financials and Funding
Specific financial details, including funding history and investors, are not publicly disclosed. However, the company has engaged in strategic partnerships, such as the licensing agreement with Alesta Therapeutics for the development and commercialization of OC-1.
Pipeline Development
1cBio's pipeline includes:
- OC-1: A first-in-class oral therapeutic targeting hypophosphatasia (HPP), currently in GLP toxicology studies, with clinical trials expected in the second half of 2025.
- OC-3: A selective PARP1 inhibitor designed to minimize hematologic toxicities associated with first-generation PARP inhibitors, aiming for efficacy in both HR-deficient and HR-proficient tumors.
- CDK7 Inhibitor: Targeting cyclin-dependent kinase 7, this program addresses transcriptional regulation and cell cycle control in cancers, including brain-penetrant inhibitors effective across breast cancer phenotypes.
Technological Platform and Innovation
1cBio's innovation is driven by:
- Proprietary Technologies: Development of small molecule inhibitors targeting specific enzymes and pathways implicated in disease pathology.
- Scientific Methodologies: Utilization of medicinal chemistry and translational sciences to design and optimize therapeutic candidates.
Leadership Team
1cBio's leadership comprises experienced drug developers with a history of advancing programs from invention to clinical trials, contributing to marketed products like XTANDI and TALZENNA.
Leadership Changes
No recent significant leadership changes have been publicly reported.
Competitor Profile
Market Insights and Dynamics
The biotechnology sector, particularly in oncology and rare diseases, is characterized by rapid innovation and significant investment. The market is competitive, with numerous companies developing targeted therapies.
Competitor Analysis
Key competitors include:
- Curis (CRIS): Focuses on developing innovative therapeutics for cancer treatment.
- SAB Biotherapeutics (SABS): Specializes in immunotherapies for infectious diseases and immune system disorders.
- Bolt Biotherapeutics (BOLT): Develops immuno-oncology therapies targeting tumors.
- Molecular Templates (MTEM): Works on engineered toxin bodies for targeted cancer treatment.
- Amgen (AMGN): A leading biotechnology company with a broad portfolio, including oncology products.
- Gilead Sciences (GILD): Focuses on antiviral drugs and expanding into oncology.
- Vertex Pharmaceuticals (VRTX): Known for cystic fibrosis treatments and expanding into other areas.
- Regeneron Pharmaceuticals (REGN): Develops medicines for eye diseases, cancer, and inflammatory conditions.
- Alnylam Pharmaceuticals (ALNY): Pioneers RNA interference therapeutics.
- Biogen (BIIB): Specializes in neurological and neurodegenerative diseases.
Strategic Collaborations and Partnerships
In January 2025, 1cBio entered an exclusive global licensing agreement with Alesta Therapeutics for OC-1, an oral therapeutic candidate for hypophosphatasia. Under this agreement, Alesta will handle development, commercialization, and manufacturing, while 1cBio is eligible for milestone payments and royalties.
Operational Insights
1cBio's strategic considerations include:
- Market Position: Focusing on precision medicines for oncology and rare diseases to address unmet needs.
- Competitive Advantages: Leveraging expertise in medicinal chemistry and translational sciences to develop differentiated therapies.
Strategic Opportunities and Future Directions
1cBio aims to:
- Advance its pipeline candidates through clinical development.
- Explore additional partnerships to enhance development and commercialization capabilities.
- Expand its portfolio to address other unmet medical needs in oncology and rare diseases.
Contact Information
For more information, visit 1cBio's official website.
Note: Specific contact details such as address, phone number, or email are not provided in the available sources.
